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Abstract
Purpose: Growth factors such as platelet-derived growth factor (PDGF) exert potent
effects on wound healing including the regeneration of periodontia. Pyridinoline cross-
linked carboxyterminal telopeptide of type I collagen (ICTP) is a well-known
biomarker of bone turnover, and as such is a potential indicator of osseous metabolic
activity. The objective of this study was to evaluate the release of the ICTP into the
periodontal wound fluid (WF) following periodontal reconstructive surgery using local
delivery of highly purified recombinant human PDGF (rhPDGF)-BB.
Methods: Forty-seven human subjects at five treatment centres possessing chronic
severe periodontal disease were monitored longitudinally for 24 weeks following
PDGF regenerative surgical treatment. Severe periodontal osseous defects were
divided into one of three groups and treated at the time of surgery with either: b-
tricalcium phosphate (TCP) osteoconductive scaffold alone (active control), b-
TCP10.3 mg/ml of rhPDGF-BB, or b-TCP11.0 mg/ml of rhPDGF-BB. WF was
harvested and analysed for local ICTP levels by radioimmunoassay. Statistical analysis
was performed using analysis of variance and an area under the curve analysis (AUC).
Results: The 0.3 and 1.0 mg/ml PDGF-BB treatment groups demonstrated increases
in the amount of ICTP released locally for up to 6 weeks. There were statistically
significant differences at the week 6 time point between b-TCP carrier alone group
versus 0.3 mg/ml PDGF-BB group (po0.05) and between b-TCP alone versus the
1.0 mg/ml PDGF-BB-treated lesions (po0.03). The AUC analysis revealed no
statistical differences amongst groups.
Conclusion: This study corroborates the release of ICTP as a measure of active bone
turnover following local delivery of PDGF-BB to periodontal osseous defects. The
amount of ICTP released from the WF revealed an early increase for all treatment
groups. Data from this study suggests that when PDGF-BB is delivered to promote
periodontal tissue engineering of tooth-supporting osseous defects, there is a direct
effect on ICTP released from the wound.
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Growth factors are required for the
regeneration of periodontal tissues.
They are intricately involved in perio-
dontal development and healing through
their effects on cell chemotaxis, prolif-
eration and differentiation (Giannobile
1996). Growth factors such as platelet-
derived growth factor (PDGF) can sti-
mulate cells involved in tissue repair
and enhance periodontal wound healing
and regeneration (Lynch et al. 1991,
Parkar et al. 2001).
Recently, an experimental perio-
dontal grafting material consisting of a
b-tricalcium phosphate (b-TCP) scaf-
fold enriched with a highly purified
recombinant human PDGF (rhPDGF-
BB) has been evaluated (Nevins et al.
2005). PDGF-BB enhances b-TCP’s
physical and mechanical actions by pro-
moting cellular ingrowth into the oss-
eous defect and bone matrix. PDGF has
been thoroughly studied in periodontics
since first discovered to promote regen-
eration of bone, cementum and perio-
dontal ligament (Lynch et al. 1989,
1991, Giannobile et al. 1994, Cho et
al. 1995, Giannobile et al. 1996, Green
et al. 1997, Nevins et al. 2003). These
studies have demonstrated the mechan-
ism of action of PDGF, showing the
presence of cell-surface receptors for
PDGF on periodontal and alveolar
bone cells, and elucidated PDGF’s sti-
mulatory effect on the DNA replication
and chemotaxis of these cells (Matsuda
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et al. 1992, McAllister et al. 1993,
Mumford et al. 2001). An initial human
clinical trial demonstrated that applica-
tion of 0.15 mg/ml of rhPDGF-BB and
0.15 mg/ml recombinant human insulin-
like growth factor I (rhIGF-I) resulted in
a significant improvement in bone fill
compared with conventional flap sur-
gery (Howell et al. 1997). In a recent
clinical trial, Nevins (2005), reported a
mean percent bone fill of 57%
with 0.3 mg/ml PDGF-BB plus b-TCP,
34% for the 1.0 mg/ml PDGF-BB
plus b-TCP, and 18% for the b-TCP
alone, respectively. Comparisons of
both concentrations of rhPDGF-BB
demonstrated statistically significant
improvements compared with the b-
TCP carrier alone for radiographic para-
meters of bone regeneration.
Pyridinoline cross-linked carboxyterm-
inal telopeptide of Type I collagen
(ICTP) has been demonstrated to be
involved in bone turnover in a variety
of clinical situations such as in osteoporo-
sis and during periodontal bone remodel-
ing (Eastell et al. 1993, Giannobile et al.
1995). The results from a single-centre
trial evaluating ICTP suggest a relation-
ship between wound repair and ICTP
release (Cooke et al. in press). This study
sought to evaluate an expanded patient
population with regard to the release of
ICTP into local periodontal wound fluid
(WF) or gingival crevicular fluid (GCF)
during periodontal repair.
The aim of this multi-centre trial was
to better understand the contribution to
wound healing of pyridinoline cross-
linked ICTP when released into perio-
dontal WF during tissue repair after
local PDGF-BB reconstructive therapy.
Material and Methods
This investigation evaluated 47 patients
from five different clinical centres,
afflicted with chronic severe periodontal
disease requiring periodontal regenera-
tive surgery. The patients in this study
were a subset of research subjects parti-
cipating in a phase III trial designed to
evaluate the safety and effectiveness of
rhPDGF-BB to promote soft- and hard-
tissue engineering of the periodontium
(Nevins et al. 2005) and those recently
reported from the single study cohort of
16 subjects (Cooke et al. in press). The
subjects provided GCF at baseline or
periodontal WF following the delivery
of grafts containing b-TCP alone or b-
TCP containing one of two dose levels
of rhPDGF-BB (0.3 or 1.0 mg/ml) to
severe periodontal osseous defects.
Informed consent was obtained at the
initial visit prior to administration of any
research procedures. The study protocol
conformed to the ethical guidelines of the
1975 Declaration of Helsinki as reflected
in obtainment of approval by the Uni-
versity of Michigan’s and the Western
Regional human subjects research review
committees.
Inclusion/exclusion criteria
Subjects were entered into the study if
they were between 25 and 75 years of
age and displayed no evidence of loca-
lized aggressive periodontitis. Patients
qualified for the study if one tooth
exhibited a soft tissue probing pocket
depth measuring 7 mm or greater, and
after surgical debridement, a 4 mm or
greater vertical bone defect (BD) was
present with at least one bony wall.
Patients were excluded if they were un-
able to maintain the health of the site or
were pregnant. The following were also
exclusionary factors at baseline: diag-
nosis of oral cancer or HIV within 6
months, previous periodontal surgery
within 1 year on the study tooth, tooth
mobility greater than grade II, radio-
graphic signs of untreated acute infec-
tion at the surgical site, or recent history
of smoking more than 20 cigarettes/day.
Randomization and surgical treatment
Subjects were randomized into one of
three treatment groups: b-TCP carrier
alone (15 patients) (active control), b-
TCP10.3 mg/ml of rhPDGF-BB (14
patients) or b-TCP11.0 mg/ml of
rhPDGF-BB (18 patients). Teeth adja-
cent to the treatment site served as
surgical controls when included as part
of the flap design.
Before surgical treatment, each sub-
ject received non-surgical therapy con-
sisting of scaling and root planing to
control the disease process and prepare
the defect site for surgical therapy.
Surgical treatment consisted of full-
thickness mucoperiosteal flaps to allow
adequate visualization of the osseous
lesion. Following debridement of the
test site, the BD was measured and if
found to be X4 mm vertically, final
subject eligibility was confirmed and
the root surfaces were decontaminated
with a tetracycline paste. The test sites
were then treated with b-TCP with
buffer alone, or buffer containing one
of two dose levels of rhPDGF-BB fol-
lowed by the securing of flaps with inter-
dental sutures to achieve primary closure.
Subjects were instructed to utilize an oral
rinse of chlorhexidine (0.12%) twice
daily for 6 weeks. Amoxicillin 500 mg
taken thrice daily for a minimum of 10
days (or another appropriate antibiotic
regimen) was also prescribed.
Periodontal WF collection
Each patient had one surgical site that
received the device: b-TCP containing
buffer alone (active control), b-TCP,
with buffer containing 0.3 mg/ml of
rhPDGF-BB, or b-TCP, with buffer
containing 1.0 mg/ml of rhPDGF-BB
that provided a WF sample. WF samples
were also collected from the teeth adja-
cent to the treatment site serving as
surgical controls. The WF samples
were taken directly from the defect site
at the periodontal pocket. The area
around each sample site was air-dried
and the supragingival plaque biofilm
removed. A sterile methylcellulose strip
(Pro Flow Inc., Amityville, NY, USA)
was gently inserted into the sulcus/pock-
et until slight resistance was felt. The
fluid sample was then collected for 10 s
and the strip was then immediately
placed into an Eppendorf tube. The
samples were subsequently kept on ice
for transport to the laboratory where
they were stored at  201C until needed
for analysis of ICTP. The collection of
WF occurred at six different time points
(Fig. 1): baseline, weeks 3, 6, 12, 18 and
24 after re-constructive surgery.
Biomarker analysis
ICTP evaluation
Frozen samples were thawed at room
temperature and the proteins were then
eluted through centrifugation  5 in
12  75 ml polypropylene tubes at
3,000 rpm for 5 min. with 20 ml phos-
phate buffered saline (pH 7.4) contain-
ing 15 nM aprotinin, 1 mM PMSF and
0.1% of human serum albumin as
described previously (Giannobile et al.
1995). GCF/WF ICTP levels were quan-
tified using radioimmunoassay (DiaSor-
in Inc., Stillwater, MN, USA) as pre-
viously described (Risteli et al. 1993).
ICTP was determined as total amount/
time of collection (pg/site/patient).
Statistical analysis
The standard statistics and statistical
modeling procedures using analysis of
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variance (ANOVA) and a Fisher’s PLSD
post hoc test at the 5% level were
performed to examine the differences
in ICTP values among the treatment
groups. A longitudinal analysis was
used to take into account non-indepen-
dence of the sample sites. Each model
was run with the mediator level area
under the curve (AUC) analysis as the
dependent variable, and each of the
surgery groups was run as the inde-
pendent variables. AUC analysis was
performed from Baseline-24 weeks.
The Baseline-24 week AUC analysis
accounts for the observation period
that includes bone repair and matura-
tion. AUC was calculated by determin-
ing the area under the line connecting
each time point of the ICTP line chart
when PWF was collected. The following
formulae were used to determine the
AUC for each of the three treatment
groups:
Baseline-24 week AUC:
1=2ðy1 þ 2y2 þ 2y3Þ þ ðy3 þ 2y4 þ 2y5
þ y6Þ
where y1 is the average ICTP at baseline
and y2, y3, y4, y5, and y6 represents
average ICTP at weeks 3, 6, 12, 18
and 24, respectively.
Statistical analysis using AUC was
performed using ANOVA Fisher’s PSLD
at the 5% level.
Results
Table 1 shows baseline patient demo-
graphics. The mean age for all patients
was 51.4 years with a range of 26–73
years. Fifty-three percentage of the
patients involved in the study were
male. A total of 11 patients in the study
were considered smokers and 36 were
considered non-smokers. The b-TCP
carrier alone group contained three cur-
rent smokers, the 0.3 mg/ml of rhPDGF-
BB group had four current smokers,
and the 1.0 mg/ml of rhPDGF-BB group
possessed four current smokers. For
the test groups, baseline mean probing
depth (PD) was 8.4 mm, baseline
clinical attachment level was 9.4 mm,
and the mean BD depth was 5.7 mm.
No statistically significant differences
were found between surgical treat-
ment groups for these pretreatment mea-
surements.
Figure 1 illustrates the timeline for
WF collections. The collection of WF
occurred at six different time points:
baseline, week 3, 6, 12, 18 and 24 after
surgery. Clinical and radiographic ex-
aminations occurred at the baseline time
point pre-surgically, week 12 and 24.
Figure 2 shows an example of the
experimental protocol including pre-
treatment, surgical treatment, and post-
treatment photographs as well as pre-
and post-treatment radiographs. The
pre-treatment radiograph shows bony
defect on the mesial root of tooth #18.
The pre-treatment PD was 7 mm. After
flap reflection and degranulation an
infrabony defect of 6 mm was present
qualifying the patient for the study. The
treatment group was then randomly
assigned and the b-TCP carrier with or
without PDGF-BB placed into infrab-
ony defect. In this case the patient
received the b-TCP carrier with
0.3 mg/ml PDGF-BB. Primary closure
of the flap was obtained with Goretex
s
sutures (W.L. Gore Co., Flagstaff, AZ,
USA). At week 24 in this case there is
now a 4 mm PD and the week 24 radio-
graph shows the infrabony defect is
absent and the crestal lamina dura is
intact. The final result showed a 48%
bone fill and 3 mm gain in clinical
attachment.
Table 2 demonstrates ICTP levels
(pg/site) over time for all groups. The
b-TCP carrier alone group shows a
decrease in the amount of ICTP released
in the WF up to week 24. The 0.3 and
1.0 mg/ml PDGF-BB groups had an
increase in the amount of ICTP released
up to 6 weeks. Statistical differences
were observed at week 6 between the
b-TCP carrier alone group and the
0.3 mg/ml (po0.05) and 1.0 mg/ml
(po0.03) PDGF-BB groups. At week
6 there is a greater than a twofold
increase in the release of ICTP from
the WF for the 0.3 and 1.0 mg/ml
PDGF-BB groups compared with the
b-TCP carrier alone. The amount of
ICTP released from the b-TCP group
was similar to the surgical control which
remained o100 pg/site for the entire
observation period (data not shown). In
addition, the AUC analysis of ICTP for
all groups over 24 weeks is also pre-
sented in Table 2. No statistical differ-
ences were observed among treatment
groups. The AUC was similar for the
0.3 mg/ml PDGF-BB group and the
1.0 mg/ml PDGF-BB group. The b-
TCP carrier alone group displayed a
trend of a lower AUC for ICTP, but
this difference was not statistically sig-
nificant. No centre effects were noted
with respect to ICTP levels among the
groups evaluated.
Discussion
The results of this study show statisti-
cally significant differences at the week
6 time point between b-TCP carrier
alone group versus 0.3 mg/ml PDGF-
BB group (po0.05) and between b-
TCP carrier alone group versus 1.0 mg/
ml PDGF-BB group (po0.03) for WF
ICTP levels. The 0.3 and 1.0 mg/ml
PDGF-BB-treated groups demonstrated
increases in the amount of ICTP
released locally for up to 6 weeks fol-
lowing regenerative surgery. The results
of this study expand up those reported in
the single-centre investigation of a panel









Number of Patients 15 14 18 47
Age
Mean 54 48 52 51.4
Range 33–71 30–64 26–73 26–73
%Males (#) 57 (8) 33 (5) 70 (12) 53 (25)
Smoking history
Current 3 4 4 11
Non-smoker 11 11 14 36
Mean PD (mm) 8.3 8.8 8.1 8.4
Mean CAL (mm) 9.2 10 9.1 9.4

















Fig. 1. Clinical Trial Study Timeline. GCF,
gingival crevicular fluid; WF, periodontal
wound fluid; exam included collection of
standard clinical parameters.
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of biomarkers including ICTP found in
16 subjects reported by Cooke et al. in
press.
For an evaluation of osseous remo-
deling following local PDGF-BB appli-
cation, we studied ICTP, a member of a
family of biomarkers which have
emerged to be valuable for bone turn-
over in a multitude of osteolytic and
osseous metabolic diseases including
periodontal disease (Eyre 1987, Gianno-
bile et al. 2003, Taba et al. 2005). Type I
collagen comprises 90% of the organic
matrix of bone and is the most abundant
collagen of osseous tissue (Narayanan &
Page 1983). Pyridinoline cross-links
represent a class of mature collagen
degradative molecules that include pyr-
idinoline, deoxypyridinoline, N-telopep-
tides, and C-telopeptides (Eyre 1987,
Calvo et al. 1996). Following procolla-
gen synthesis and release into the matur-
ing extracellular matrix, pyridinoline
cross-links are formed in type I collagen
by the enzyme lysyl oxidase on lysine
and hydroxylysine residues in the car-
boxy- and amino-terminal telopeptide
regions, increasing the mechanical sta-
bility of the structure (Last et al. 1990).
Subsequent to osteoclastic bone re-sorp-
tion and collagen matrix degradation,
cross-linked telopeptides of type I col-
lagen are released into the circulation.
As cross-linked telopeptides result from
post-translational modification of col-
lagen molecules, they cannot be reused
during collagen synthesis, and are there-
fore precise indicators of bone re-sorp-
tion (Eriksen et al. 1993). In addition,
contrary to other tissues, pyridinoline
cross-links are specific to bone turnover
(Charles et al. 1994).
Pyridinoline cross-links represent a
potentially valuable diagnostic aid in
periodontics, as biochemical markers
specific for bone turnover may be useful
in differentiating the presence of gingi-
val inflammation from active perio-
dontal and peri-implant bone turnover
(Golub et al. 1997). Several investiga-
tions have recently explored the ability
of pyridinoline cross-links to detect
bone resorption in lesions of perio-
dontitis (Talonpoika & Hämaläinen
1994, Giannobile et al. 1995, Golub et
al. 1997, Shibutani et al. 1997, Palys et
al. 1998) and peri-implantitis (Oringer
et al. 1998). For instance, in a study of
25 periodontitis patients treated with
scaling and root planing, significant
correlations between GCF ICTP level
and clinical periodontal disease para-
meters were found (Al-Shammari et al.
2001). In addition, elevated GCF ICTP
levels at baseline, especially at shallow
sites, were found to be predictive of
subsequent attachment loss as early as
one month after sampling (Oringer et al.
2002).
To monitor treatment, other studies
have demonstrated that GCF ICTP
levels are correlated to disease resolu-
tion. Golub et al. (1997)found that treat-
ment of 18 chronic periodontitis patients
with a matrix metalloproteinase inhibi-
tor (subantimicrobial doxycycline hyclate,
SDH) resulted in a 70% reduction in
GCF ICTP levels after 1 month, con-
comitant with a 30% reduction in col-
lagenase levels. Furthermore, Gapski et
al. (2004) found that treatment of 24
chronic periodontitis patients with
access flap surgery and SDH resulted
in a potent decrease in ICTP levels soon
after the surgical therapy at 3 months
while the placebo controls demonstrated
no change or increases in ICTP levels
over a 12-month observation period.
In another related study PDGF-BB
was found to have a direct effect on
growth factors released from perio-
dontal wounds. VEGF was induced dur-
ing early wound repair (i.e. 3–5 days),
while exogenous PDGF-BB possibly
reduced the release of endogenous
PDGF-AB from the wound site after
several days of healing. There was also
a marked increase in bone turnover
during the first few days of wound
healing when PDGF-BB was added to
the osteoconductive scaffold, as the
amount of ICTP release from the wound
was increased for the early time points
(Cooke et al. in press). In addition, non-
surgical sites displayed very low (in
Fig. 2. Pre-treatment, surgical procedure, and week 24 radiographs of a defect treated with
the local delivery of 0.3 mg/ml of rhPDGF and b-tricalcium phosphate. (a) Pre-treatment
radiograph shows bony defect on the mesial of tooth #18. (b) After flap reflection and
degranulation an infrabony defect of 6 mm is present. (c) Bone graft placed into infrabony
defect. (d) Week 24 post-operative radiograph shows the healing of the infrabony defect. The
defect shows 48% bone fill and the crestal lamina dura intact.
Table 2. Effect of PDGF-BB on wound fluid ICTP levels
Time (weeks) ICTP (pg/10 s) (mean1SEM)
Carrier rhPDGF-BB rhPDGF-BB
(0.3 mg/ml) (1.0 mg/ml)
Baseline 64.9  42.7 113.1  43.7 109.7  54.6
3 41.9  33.6 72.6  39.1 103.1  33.7
6 45.1  36.2 125.9  63.1n 139.7  58.5n
12 60.0  35.5 65.6  27.4 63.7  25.4
18 50.7  50.7 63.3  27.6 60.2  27.6
24 74.1  50.7 63.3  41.7 57.5  21.7
Overall (AUC) 437.5  287.1 641.7  164.1 672.8  183.0
npo0.05 versus carrier. ICTP, carboxyterminal telopeptide of Type I collagen; AUC, area under the
curve.
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general, non-detectable levels of ICTP)
when compared with surgical wound
sites (Cooke et al. 2006).
This study evaluated release of ICTP
following PDGF-BB application as a
measure of active bone turnover in a
multi-centre investigation. The amount
of ICTP released from the WF showed
early increases for the 0.3 mg/ml PDGF-
BB and the 1.0 mg/ml PDGF-BB groups
compared with scaffold alone. In parti-
cular, at 6 weeks, sites treated with
PDGF-BB showed a greater amount of
ICTP release from the WF. However,
the total amount of released ICTP over
time, as shown by AUC analysis, was
unchanged with active treatment. Final
clinical outcomes from the multi-centre
parent study show an average increase
in linear bone growth of 2.6 mm for the
0.3 mg/ml PDGF-BB group, 1.5 mm for
the 1.0 mg/ml PDGF-BB group, and
0.9 mm for the b-TCP carrier alone
group (Nevins et al. 2005). Therefore,
in contrast to previous studies where
ICTP levels were indicative of further
disease, the present study demonstrates
that elevated ICTP as a result of a
regenerative attempt is suggestive as a
sign of bone turnover given the inter-
relationship between bone formation
and bone resorption. In addition, as
could be anticipated with periodontal
regeneration, early events are likely
decisive to treatment outcome.
In conclusion, data from this study
shows that when rhPDGF-BB is deliv-
ered to promote periodontal tissue engi-
neering of tooth-supporting osseous
defects, there is a direct effect on ICTP
released from the wound. Future studies
with expanded patient populations and
earlier time intervals of WF collection
will be needed to better understand the
effects of rhPDGF-BB on periodontal
wound healing.
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Clinical Relevance
PDGF has shown potential to regen-
erate periodontal defects. However,
little information is available regard-
ing the mechanisms on how PDGF
regulates bone turnover. This study
examined 47 patients following
reconstructive periodontal surgery
combining PDGF treatment on the
expression of a key marker of bone
turnover, the pyridinoline cross-link
of type I collagen (ICTP). It was
noted that following therapy, ICTP
was strongly induced during the
early stages of tissue repair. These
results provide better information on
the role of PDGF in affecting perio-
dontal wound healing and bone turn-
over.
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